IL2 and chronic graft versus host disease: A phase I dose-escalation trial of IL-2 in 28 patients with chronic GVHD after stem cell transplantation demonstrated beneficial effects of low-dose IL-2 by inducing selective expansion of functional Tregs and clinical improvement [23].